2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

2:30PM-4:00PM: Abstract Number: 1831

Intestinal Inflammatory Regulation in Murine and Human Spondyloarthropathy Requires High-Affinity T Cell Receptor-Zeta Chain-Associated Protein (ZAP)70-Mediated Runt-Related Transcription Factor (Runx)3 Activity

4M088 ACR Abstract: Spondyloarthritis Incl PsA–Basic Science (1828–1833)

2:30PM-4:00PM: Abstract Number: 1865

Ixekizumab Significantly Improves Self-Reported Overall Functioning and Health in Patients with Active As/Radiographic Axial Spa Naive to Biologic DMARD Therapy: 16‑Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial

4M089 ACR Abstract: Spondyloarthritis Incl PsA–Clinical III: Treatment of Axial SpA (1864–1869)

2:30PM-4:00PM: Abstract Number: 1864

Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial

4M089 ACR Abstract: Spondyloarthritis Incl PsA–Clinical III: Treatment of Axial SpA (1864–1869)

2:30PM-4:00PM: Abstract Number: 1861

Lipid Screening in Medicare Beneficiaries with Rheumatoid Arthritis

4M086 ACR Abstract: RA–DX, Manifestations, & Outcomes II: DX & Prognosis I (1858–1863)

2:30PM-4:00PM: Abstract Number: 1885

Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s disease): A Multicenter Study of 224 Patients

4M091 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os I: Population-Based Studies(1881–1886)

2:30PM-4:00PM: Abstract Number: 1890

Longitudinal Deep Learning on Electronic Health Record Data to Predict Future Rheumatoid Arthritis Disease Activity

4M094 ACR/ARHP Abstract: Health Services Research I: Focus on Big Data (1887–1892)

2:30PM-4:00PM: Abstract Number: 1823

Loss of Synovial Tissue Resident Macrophages Permits Monocyte to Macrophage Differentiation and Inflammation in Hupo Mice

4M085 ACR Abstract: RA–Animal Models (1822–1827)

2:30PM-4:00PM: Abstract Number: 1856

Low Aspirin Use and High Prevalence of Preeclampsia Risk Factors Among Pregnant Women in a Multi-National SLE Inception Cohort

4M087 ACR Abstract: Reproductive Issues in Rheumatic Disorders (1852–1857)

2:30PM-4:00PM: Abstract Number: 1857

Low Molecular Weight Heparin and Aspirin Combination Therapy Modulates Th1/Th2 Cell Imbalance in Pregnant Patients with Antiphospholipid Antibody-Associated Recurrent Pregnancy Loss

4M087 ACR Abstract: Reproductive Issues in Rheumatic Disorders (1852–1857)

2:30PM-4:00PM: Abstract Number: 1876

Machine Learning Classification of Peripheral Blood Gene Expression Identifies a Subset of Patients with Systemic Sclerosis Most Likely to Show Clinical Improvement in Response to Hematopoietic Stem Cell Transplant

4M090 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical II: Clinical Trials II (1875–1880)

2:30PM-4:00PM: Abstract Number: 1846

Menarchal Status at Diagnosis and Final Height in Females with Childhood-Onset Systemic Lupus Erythematosus

4M084 ACR Abstract: Pediatric Rheum–Clinical I: Outcomes & Comorbidities (1846–1851)

2:30PM-4:00PM: Abstract Number: 1824

Osteoclast Derived-Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss

4M085 ACR Abstract: RA–Animal Models (1822–1827)

2:30PM-4:00PM: Abstract Number: 1853

Paternal Use of Methotrexate (MTX) and Congenital Malformations – a Systematic Review and Meta-Analysis

4M087 ACR Abstract: Reproductive Issues in Rheumatic Disorders (1852–1857)

2:30PM-4:00PM: Abstract Number: 1892

Patient and Health System Characteristics Associated with Receipt of Disease Modifying Anti-Rheumatic Drugs in a National VA Sample

4M094 ACR/ARHP Abstract: Health Services Research I: Focus on Big Data (1887–1892)

2:30PM-4:00PM: Abstract Number: 1891

Patterns of Biosimilar Use in the Rheumatology Informatics System for Effectiveness (RISE) Registry

4M094 ACR/ARHP Abstract: Health Services Research I: Focus on Big Data (1887–1892)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].